Crescentic glomerulonephritis;Glomérulonéphrites extracapillaires

Nephrologie et Therapeutique

Volumn 2, Issue 7, 2006, Pages 446-460

  Esnault, Vincent Louis Marie ^a   Moreau, Anne ^a   Testa, Angelo ^b   Besnier, Dominique ^c  

^a HÔTEL DIEU   (France)

^b Association de Dialyse ECHO   (France)

^c Centre Hospitalier de Saint Nazaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CD20 ANTIBODY; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; LYMPHOCYTE ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENTAMIDINE; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

DISEASE CLASSIFICATION; GLOMERULUS BASEMENT MEMBRANE; GOODPASTURE SYNDROME; HEMATURIA; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOGENESIS; KIDNEY BIOPSY; KIDNEY FAILURE; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; PLASMAPHERESIS; PROGNOSIS; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REMISSION; SHORT SURVEY; STEROID THERAPY; SYMPTOM; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

AUTOANTIBODIES; CELL DIVISION; DIAGNOSIS, DIFFERENTIAL; GLOMERULONEPHRITIS; HUMANS; KIDNEY GLOMERULUS;

EID: 33845585833     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2006.06.007     Document Type: Short Survey

References (183)

1. Baldwin D.S., Neugarten J., Feiner H.D., Gluck M., and Spinowititz B. The existence of a protracted course in crescentic glomerulonephritis. Kidney Int. 31 (1987) 790-794
2. Couser W.G. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am. J. Kidney Dis. 11 (1988) 449-464
3. Cameron J.S. The nosology of crescentic nephritis. Nephrologie 13 (1992) 243-246
4. Bonsib S.M. Glomerular basement membrane discontinuities: scanning electron microscopic study of acellular glomeruli. Am. J. Pathol. 119 (1985) 357-360
5. Erlich J.H., Holdsworth S.R., and Tipping P.G. Tissue factor initiates fibrin deposition and promotes major histocompatibility complex class II expression in crescentic glomerulonephritis. Am. J. Pathol. 150 (1997) 873-880
6. Drew A.F., Tucker H.L., Liu H., Witte D.P., Degen J.L., and Tipping P.G. Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice. Am. J. Physiol. 281 (2001) F1157-F1163
7. Kitching A.R., Holdsworth S.R., and Ploplis V.A. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J. Exp. Med. 185 (1997) 963-968
8. Li S., Kurts C., Kontgen F., Holdsworth S.R., and Tipping P.G. Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. J. Exp. Med. 188 (1998) 597-602
9. Cunningham M.A., Rondeau E., Chen X., Coughlin S.R., Holdsworth S.R., and Tipping P.G. Protease-activated receptor 1 mediates thrombin-dependant, cell-mediated renal inflammation in crescentic glomerulonephritis. J. Exp. Med. 191 (2000) 455-462
10. Pober J.S., and Cotran R.S. The role of endothelial cells in inflammation. Transplantation 50 (1990) 537-544
11. Atkins R.C., Nikolic-Paterson D.J., Song Q., and Lan H.Y. Modulators of crescentic glomerulonephritis. J. Am. Soc. Nephrol. 11 (1996) 2271-2278
12. Le Hir M., Haas C., Marino M., and Ryffel B. Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. Lab. Invest. 78 (1998) 1625-1631
13. Tomita N., Morishita R., and Lan H.Y. In vivo administration of a nuclear transcription factor-kappa-B decoy suppresses experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. 11 (2000) 1244-1252
14. Karkar A.M., Smith J., and Pusey C.D. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. Nephrol. Dial. Transplant. 16 (2001) 518-524
15. Lan H.Y., Nikolic-Paterson D.J., Zarama M., Vannice J.L., and Atkins R.C. Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int. 43 (1993) 479-485
16. Nishikawa K., Guo Y.J., Miyasaka M., Tamatani T., Collins A.B., Sy M.S., et al. Antibodies to intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 prevent crescent formation in rat autoimmune glomerulonephritis. J. Exp. Med. 177 (1993) 667-677
17. Brad H., Rovin L.A., and Phan T. Chemotactic factors and renal inflammation. Am. J. Kidney Dis. 31 (1998) 1065-1084
18. Brown F.G., Nikolic-Paterson D.J., Hill P.A., Isbel N.M., Dowling J., Metz C.M., et al. Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J. Am. Soc. Nephrol. 13 suppl. 1 (2002) S7-S13
19. Segerer S., Cui Y., Hudkins K.L., Goodpaster T., Eitner F., Mack M., et al. Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomerulonephritis. J. Am. Soc. Nephrol. 11 (2000) 2231-2242
20. Wada T., Furuichi K., Segawa-Takaeda C., Shimizu M., Sakai N., Takeda S.I., et al. MIP-1-alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int. 56 (1999) 995-1003
21. Stokes M.B., Hudkins K.L., Zaharia V., Taneda S., and Alpers C.E. Up-regulation of extracellular matrix proteoglycans and collagen type I in human crescentic glomerulonephritis. Kidney Int. 59 (2001) 532-542
22. Cybulsky A.V. Extracellular matrix as a determinant of signaling responses in glomerular epithelial cells. Kidney Int. 56 (1999) 1242-1246
23. Hayashi K., Horikoshi S., Osada S., Shofuda K., Shirato I., and Tomino Y. Macrophage-derived MT1-MMP and increased MMP-2 activity are associated with glomerular damage in crescentic glomerulonephritis. J. Pathol. 191 (2000) 299-305
24. Le Hir M., Keller C., Eschmann V., Hahnel B., Hosser H., and Kriz W. Podocyte bridges between the tuft and Bowman's capsule: an early event in experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. 12 (2001) 2060-2071
25. Tipping P.G., Huang X.R., Qi M., Van G.Y., and Tang W.W. Crescentic glomerulonephritis in CD4- and CD8-deficient mice. Requirement for CD4 but not CD8 cells. Am. J. Pathol. 152 (1998) 1541-1548
26. Timoshanko J.R., Kitching A.R., Holdsworth S.R., and Tipping P.G. Interleukin-12 from intrinsic cells is an effector of renal injury in crescentic glomerulonephritis. J. Am. Soc. Nephrol. 12 (2001) 464-471
27. Kitching A.R., Holdsworth S.R., and Tipping P.G. IFN-gamma mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis. J. Am. Soc. Nephrol. 10 (1999) 752-759
28. Cook H.T., Singh S.J., Wembridge D.E., Smith J., Tam F.W., and Pusey C.D. Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats. Kidney Int. 55 (1999) 1319-1326
29. Kitching A.R., Tipping P.G., Timoshanko J.R., and Holdsworth S.R. Endogenous interleukin-10 regulates Th1 responses that induce crescentic glomerulonephritis. Kidney Int. 57 (2000) 518-525
30. Kitching A.R., Tipping P.G., Mutch D.A., Huang X.R., and Holdsworth S.R. Interleukin-4 deficiency enhances Th1 responses and crescentic glomerulonephritis in mice. Kidney Int. 53 (1998) 112-118
31. Reynolds J., Norgan V.A., Bhambra U., Smith J., Cook H.T., and Pusey C.D. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J. Am. Soc. Nephrol. 13 (2002) 359-369
32. Tipping P.G., Kitching A.R., Cunningham M.A., and Holdsworth S.R. Immunopathogenesis of crescentic glomerulonephritis. Curr. Opin. Nephrol. Hypertens. 8 (1999) 281-286
33. Magil A.B. Histogenesis of glomerular crescents: immunohistochemical demonstration of cytokeratin in crescent cells. Am. J. Pathol. 120 (1985) 222-229
34. Bolton W.K., Innes D.J., Sturgill B.C., and Kaiser D.L. T-cells and macrophages in rapidly progressive glomerulonephritis: clinicopathologic correlations. Kidney Int. 32 (1987) 869-876
35. Cockwell P., Howie A.J., Adu D., and Savage C.O. In-situ analysis of C-C chemokine mRNA in human glomerulonephritis. Kidney Int. 54 (1998) 827-836
36. Cunningham M.A., Huang X.R., Dowling J.P., Tipping P.G., and Holdsworth S.R. Effectors of cell-mediated immunity are prominent in "pauci-immune" glomerulonephritis. J. Am. Soc. Nephrol. 10 (1999) 499-506
37. Boucher A., Droz D., Adafer E., and Noel L.H. Relationship between the integrity of Bowman's capsule and the composition of cellular crescents in human crescentic glomerulonephritis. Lab. Invest. 56 (1987) 526-533
38. Li H.L., Hancock W.W., Dowling J.P., and Atkins R.C. Activated (IL-2R+) intraglomerular mononuclear cells in crescentic glomerulonephritis. Kidney Int. 39 (1991) 793-798
39. Lan H.Y., Nikolic-Paterson D.J., and Atkins R.C. Involvement of activated periglomerular leukocytes in the rupture of Bowman's capsule and glomerular crescent progression in experimental glomerulonephritis. Lab. Invest. 67 (1992) 743-751
40. Border W.A., and Noble N.A. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int. 51 (1997) 1388-1396
41. Border W.A., Noble N.A., Yamamoto T., Harper J.R., Yamaguchi Y., Pierschbacher M.D., et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360 (1992) 361-364
42. Peters H., Border W.A., and Noble N.A. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. Kidney Int. 57 (2000) 1493-1501
43. Yoshioka K., Takemura T., Tohda M., Akano N., Miyamoto H., Ooshima H., et al. Glomerular localization of type III collagen in human kidney disease. Kidney Int. 35 (1989) 1203-1211
44. Glassock R.J., Lerner R.A., and Rees A.J. The role of antiglomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. Milestones in nephrology. J. Am. Soc. Nephrol. 10 (1999) 1389-1404
45. Levy J.B., Turner A.N., Rees A.J., and Pusey C.D. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann. Intern. Med. 134 (2001) 1033-1042
46. David M., Borza D.B., Leinonen A., Belmont J.M., and Hudson B.G. Hydrophobic amino acid residues are critical for the immunodominant epitope of the Goodpasture autoantigen. A molecular basis for the cryptic nature of the epitope. J. Biol. Chem. 276 (2001) 6370-6377
47. Gunnarsson A., Hellmark T., and Wieslander J. Molecular properties of the Goodpasture epitope. J. Biol. Chem. 275 (2000) 30844-30848
48. Kalluri R., Torre A., Shield III C.F., Zamborsky E.D., Werner M.C., Suchin E., et al. Identification of alpha3, alpha4, and alpha5 chains of type IV collagen as autoantigens for Alport posttransplant antiglomerular basement membrane antibodies. Transplantation 69 (2000) 679-683
49. Kalluri R., Danoff T.M., Okada H., and Neilson E.G. Susceptibility to antiglomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J. Clin. Invest. 100 (1997) 2263-2275
50. Rutgers A., Meyers K.E., Canziani G., Kalluri R., Lin J., and Madaio M.P. High-affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha (IV) NC1 collagen. Kidney Int. 58 (2000) 115-122
51. De Vriese A.S., Endlich K., Elger M., Lameire N.H., Atkins R.C., Lan H.Y., et al. The role of selectins in glomerular leukocyte recruitment in rat antiglomerular basement membrane glomerulonephritis. J. Am. Soc. Nephrol. 10 (1999) 2510-2517
52. Suzuki Y., Shirato I., Okumura K., Ravetch J.V., Takai T., Tomino Y., et al. Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int. 54 (1998) 1166-1174
53. Bernis P., Hamels J., Quoidbach A., Mahieu P., and Bouvy P. Remission of Goodpasture's syndrome after withdrawal of an unusual toxic. Clin. Nephrol. 23 (1985) 312-317
54. Guérin V., Rabian C., Noel L.H., Droz D., Baron C., Lallemand F., et al. Antiglomerular basement membrane disease after lithotripsy. Lancet 1 (1990) 856-857
55. Tomosugi N.I., Cashman S.J., Hay H., Pusey C.D., Evans D.J., Shaw A., et al. Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1. J. Immunol. 142 (1989) 3083-3090
56. Fries J.W., Mendrick D.L., and Rennke H.G. Determinants of immune complex-mediated glomerulonephritis. Kidney Int. 34 (1988) 333-345
57. Conlon P.J., Jefferies F., Krigman H.R., Corey G.R., Sexton D.J., and Abramson M.A. Predictors of prognosis and risk of acute renal failure in bacterial endocarditis. Clin. Nephrol. 49 (1998) 96-101
58. Montseny J.J., Meyrier A., Kleinknecht D., and Callard P. The current spectrum of infectious glomerulonephritis. Experience with 76 patients and review of the literature. Medicine 74 (1995) 63-73
59. Jardim H.M., Leake J., Risdon R.A., Barratt T.M., and Dillon M.J. Crescentic glomerulonephritis in children. Pediatr. Nephrol. 6 (1992) 231-235
60. Haffner D., Schindera F., Aschoff A., Matthias S., Waldherr R., and Scharer K. The clinical spectrum of shunt nephritis. Nephrol. Dial. Transplant. 12 (1997) 1143-1148
61. Kannan S., and Mattoo T.K. Diffuse crescentic glomerulonephritis in bacterial endocarditis. Pediatr. Nephrol. 16 (2001) 423-428
62. Fairley C., Mathews D.C., and Becker G.J. Rapid development of diffuse crescents in post-streptococcal glomerulonephritis. Clin. Nephrol. 28 (1987) 256-260
63. Angangco R., Thiru S., and Oliveira D.B. Pauci-immune glomerulonephritis associated with bacterial infection. Nephrol. Dial. Transplant. 8 (1993) 754-756
64. Choi H.K., Lamprecht P., Niles J.L., Gross W.L., and Merkel P.A. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum. 43 (2000) 226-231
65. Taskapan H., Oymak O., Dogukan A., Ozbakir O., and Utas C. Transformation of hepatitis B virus-related membranous glomerulonephritis to crescentic form. Clin. Nephrol. 54 (2000) 161-163
66. D'Amico G., and Fornasieri A. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am. J. Kidney Dis. 25 (1995) 361-369
67. Weber M., Köhler H., Fries J., Thoenes W., and Meyer zum Büschenfelde K.H. Rapidly progressive glomerulonephritis in IgA/IgG cryoglobulinemia. Nephron 41 (1985) 258-261
68. Esnault V.L. Atteintes rénales au cours des vascularites. Presse Med. 30 (2001) 1119-1129
69. Detwiler R.K., Singh H.K., Bolin Jr. P., and Jennette J.C. Cytomegalovirus-induced necrotizing and crescentic glomerulonephritis in a renal transplant patient. Am. J. Kidney Dis. 32 (1998) 820-824
70. Connolly J.O., Weston C.E., and Hendry B.M. HIV-associated renal disease in London hospitals. Q. J. Med. 88 (1995) 627-634
71. Cameron J.S. Lupus nephritis. J. Am. Soc. Nephrol. 10 (1999) 413-424
72. Lefkowith J.B., and Gilkeson G.S. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum. 39 (1996) 894-903
73. Droz D., Nochy D., Noel L.H., Heudes D., Nabarra B., and Hill G.S. Thrombotic microangiopathies: renal and extrarenal lesions. Adv. Nephrol. Necker Hosp. 30 (2000) 235-259
74. Descombes E., Droz D., Drouet L., Grunfeld J.P., and Lesavre P. Renal vascular lesions in lupus nephritis. Medicine 76 (1997) 355-368
75. Davin J.C., ten Berge I.J., and Weening J.J. What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis?. Kidney Int. 59 (2001) 823-834
76. Pillebout E., Thervet E., Hill G., Alberti C., Vanhille P., and Nochy D. Henoch-Schonlein Purpura in adults: outcome and prognostic factors. J. Am. Soc. Nephrol. 13 (2002) 1271-1278
77. Isaacs J.D., Evans D.J., and Pusey C.D. Mesangial IgA disease with crescent formation during pregnancy: postpartum treatment with immunosuppression. Nephrol. Dial. Transplant. 5 (1990) 619-622
78. Aggarwal M., Manske C.L., Lynch P.J., and Paller M.S. Henoch-Schönlein vasculitis as a manifestation of IgA-associated disease in cirrhosis. Am. J. Kidney Dis. 20 (1992) 400-402
79. Diaz-Tejeiro R., Maduell F., Diez J., Esparza N., Errasti P., Purroy A., et al. Loss of renal graft due to recurrent IgA nephropathy with rapidly progressive course: an unusual clinical evolution. Nephron 54 (1990) 341-343
80. Esnault V.L., Ronda N., Jayne D.R., and Lockwood C.M. Association of ANCA isotype and affinity with disease expression. J. Autoimmun. 6 (1993) 197-205
81. Haas M., Jafri J., Bartosh S.M., Karp S.L., Adler S.G., and Meehan S.M. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. Am. J. Kidney Dis. 36 (2000) 709-718
82. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 37 (1994) 187-192
83. Hattori M., Kurayama H., and Koitabashi Y. Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in children. J. Am. Soc. Nephrol. 12 (2001) 1493-1500
84. Esnault V.L., Soleimani B., Keogan M.T., Brownlee A.A., Jayne D.R., and Loskwood C.M. Association of IgM with IgG ANCA in patients presenting with pulmonary hemorrhage. Kidney Int. 41 (1992) 1304-1310
85. Savage C.O. ANCA-associated renal vasculitis. Kidney Int. 60 (2001) 1614-1627
86. Schlieben D.J., Korbet S.M., Kimura R.E., Schwartz M.M., and Lewis E.J. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am. J. Kidney Dis. 45 (2005) 758-761
87. Xiao H., Heeringa P., Hu P., Liu Z., Zhao M., Aratani Y., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110 (2002) 955-963
88. Hagen E.C., Daha M.R., Hermans J., Andrassy K., Csernok E., Gaskin G., et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR project for ANCA assay standardization. Kidney Int. 53 (1998) 743-753
89. Boomsma M.M., Stegeman C.A., van der Leij M.J., Oost W., Hermans J., Kallenberg C.G., et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43 (2000) 2025-2033
90. Cohen Tervaert J.W., Huitema M.G., Hene R.J., Sluiter W.J., The T.H., Van Der Hem G.K., et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 336 (1990) 709-711
91. Stegeman C.A., Cohen Tervaert J.W., Sluiter W.J., Manson W.L., De Jong P.E., and Kallenberg C.G. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann. Intern. Med. 120 (1994) 12-17
92. Falk R.J., Terrel R.S., Charles L.A., and Jennette J.C. Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl. Acad. Sci. USA 87 (1990) 4115-4119
93. Weidner S., Neupert W., Goppelt-Struebe M., and Rupprecht H.D. Antineutrophil cytoplasmic antibodies induce monocytes to produce oxygen radicals in vitro. Arthritis Rheum. 44 (2001) 1698-1706
94. Yang J.J., Tuttle R.H., Hogan S.L., Taylor J.G., Phillips B.D., Falk R.J., et al. Target antigens for anti-neutrophil cytoplasmic antibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils. Clin. Exp. Immunol. 121 (2000) 165-172
95. Witko-Sarsat V., Lesavre P., Lopez S., Bessou G., Hieblot C., Prum B., et al. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J. Am. Soc. Nephrol. 10 (1999) 1224-1233
96. Hess C., Sadallah S., and Schifferli J.A. Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. Blood 96 (2000) 2822-2827
97. Porges A.J., Redecha P.B., Kimberly W.T., Csernok E., Gross W.L., and Kimberly R.P. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc-gamma-RIIa. J. Immunol. 153 (1994) 1271-1280
98. Kocher M., Edberg J.C., Fleit H.B., and Kimberly R.P. Antineutrophil cytoplasmic antibodies preferentially engage Fc gammaRIIIb on human neutrophils. J. Immunol. 161 (1998) 6909-6914
99. Ben-Smith A., Dove S.K., Martin A., Wakelam M.J., and Savage C.O. Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fcgamma receptor ligation. Blood 98 (2001) 1448-1455
100. Reumaux D., Vossebeld P.J., Roos D., and Verhoeven A.J. Effect of tumor necrosis factor-induced integrin activation of Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood 86 (1995) 3189-3195
101. Radford D.J., Luu N.T., Hewins P., Nash G.B., and Savage C.O. Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum. 44 (2001) 2851-2861
102. Grimminger F., Hattar K., Papavassilis C., Temmesfeld B., Csernok E., Gross W.L., et al. Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogeneous arachidonic acid and leukotriene B4 generation. J. Exp. Med. 184 (1996) 1567-1572
103. Taekema-Roelvink M.E., Kooten C., Kooij S.V., Heemskerk E., and Daha M.R. Proteinase 3 enhances endothelial monocyte chemoattractant protein-1 production and induces increased adhesion of neutrophils to endothelial cells by upregulating intercellular cell adhesion molecule-1. J. Am. Soc. Nephrol. 12 (2001) 932-940
104. Harper L., Ren Y., Savill J., Adu D., and Savage C.O. Antineutrophil cytoplasmic antibodies induce reactive oxygen-dependent dysregulation of primed neutrophil apoptosis and clearance by macrophages. Am. J. Pathol. 157 (2000) 211-220
105. Gilligan H.M., Bredy B., Brady H.R., Hebert M.J., Slayter H.S., Xu Y., et al. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J. Exp. Med. 184 (1996) 2231-2241
106. Patry Y.C., Trewick D.C., Gregoire M., Audrain M., Moreau A.M., Muller J.Y., et al. Rats injected with syngenic rat apoptotic neutrophils develop antineutrophil cytoplasmic antibodies. J. Am. Soc. Nephrol. 12 (2001) 1764-1768
107. Esnault V.L. Apoptosis: the central actor in the three hits that trigger anti-neutrophil cytoplasmic antibody-related systemic vasculitis. Nephrol. Dial. Transplant 17 (2002) 1725-1728
108. King W.J., Brooks C.J., Holder R., Hughes P., Adu D., and Savage C.O. T lymphocyte responses to ANCA antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission. Clin. Exp. Immunol. 112 (1998) 529-546
109. Stegeman C.A., Cohen Tervaert J.W., Huitema M.G., and Kallenberg C.G. Serum markers of T-cell activation in relapses of Wegener's granulomatosis. Clin. Exp. Immunol. 91 (1993) 415-420
110. Esnault V.L. ANCA-positive vasculitis and alpha1-antitrypsin deficiency: could free ANCA antigens released by neutrophils mediate vasculitic lesions?. Nephrol. Dial. Transplant. 12 (1997) 249-251
111. Esnault V.L., Audrain M.A., and Sesboüé R. Alpha1-antitrypsin phenotyping in ANCA-associated diseases: one of several arguments for protease/antiprotease imbalance in systemic vasculitis. Exp. Clin. Immunogenet. 14 (1997) 206-213
112. Esnault V.L., Testa A., Audrain M., Rogé C., Hamidou M., Barrier J.H., et al. Alpha1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int. 43 (1993) 1329-1332
113. Segelmark M., Elzouki A., Wieslander J., and Eriksson S. The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int. 48 (1995) 844-850
114. Andrassy K., Küster S., Koderisch J., Waldherr R., and Ritzt E. Rapidly progressive glomerulonephritis: analysis of prevalence and clinical course. Nephron 59 (1991) 206-212
115. Bajema I.M., Hagen E.C., Ferrario F., Waldherr R., Noel L.H., Hermans J., et al. Renal granulomas in systemic vasculitis. EC/BCR project for ANCA assay standardization. Clin. Nephrol. 48 (1997) 16-21
116. Lane S.E., Scott D.G., Heaton A., and Watts R.A. Primary renal vasculitis in Norfolk: increasing incidence or increasing recognition?. Nephrol. Dial. Transplant. 15 (2000) 23-27
117. Luqmani R.A., Bacon P.A., Moots R.J., Janssen B.A., Pall A., Emery P., et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. Q. J. Med. 87 (1994) 671-678
118. Niles J.L., Bottinger E.P., Saurina G.R., Kelly K.J., Pan G., Collins A.B., et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch. Intern. Med. 156 (1996) 440-445
119. Savage C.O., Pusey C.D., Bowman C., Rees A.J., and Lockwood C.M. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. BMJ 292 (1986) 301-304
120. Franssen C.F., Gans R.O., Arends B., Hageluken C., ter Wee P.M., Gerlag P.G., et al. Differences between antimyeloperoxidase- and anti-proteinase 3-associated renal disease. Kidney Int. 47 (1995) 193-199
121. Franssen C.F., Stegeman C.A., Oost-Kort W.W., Kallenberg C.G., Limburg P.C., Tiebosch A., et al. Determinants of renal outcome in antimyeloperoxidase-associated necrotizing crescentic glomerulonephritis. J. Am. Soc. Nephrol. 9 (1998) 1915-1923
122. Westman K.W., Bygren P.G., Olsson H., Ranstam J., and Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J. Am. Soc. Nephrol. 9 (1998) 842-852
123. Hogan S.L., Falk R.J., Chin H., Cai J., Jennette C.E., Jennette J.C., et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 143 (2005) 621-631
124. Hogan S.L., Nachman P.H., Wilkman A.S., Jennette J.C., and Falk R.J. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. 7 (1996) 23-32
125. Bajema I.M., Hagen E.C., Hermans J., Noel L.H., Waldherr R., Ferrario F., et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 56 (1999) 1751-1758
126. de Lind van Wijngaarden R.A., Hauer H.A., Wolterbeek R., Jayne D.R., Gaskin G., Rasmussen N., et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J. Am. Soc. Nephrol. 17 (2006) 2264-2274
127. Mekhail T.M., and Hoffman G.S. Long-term outcome of Wegener's granulomatosis in patients with renal disease requiring dialysis. J. Rheumatol. 27 (2000) 1237-1240
128. Matteson E.L., Gold K.N., Bloch D.A., and Hunder G.G. Long-term survival of patients with Wegener's granulomatosis from the American college of rheumatology Wegener's granulomatosis classification criteria cohort. Am. J. Med. 101 (1996) 129-134
129. Talar-Williams C., Hijazi Y.M., Walther M.M., Linehan W.M., Hallahan C.W., Lubensky I., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann. Intern. Med. 124 (1996) 477-484
130. De Groot K., Adu D., and Savage C.O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant. 16 (2001) 2018-2027
131. Jayne D.R. Update on the European vasculitis study group trials. Curr. Opin. Rheumatol. 13 (2001) 48-55
132. Esnault V.L., Testa A., Jayne D.R., Soulillou J.P., and Guenel J. Influence of immunoadsorption on the removal of immunoglobuline G autoantibodies in crescentic glomerulonephritis. Nephron 65 (1993) 180-184
133. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
134. Schmitt W.H., Hagen E.C., Neumann I., Nowack R., Flores-Suarez L.F., van der Woude F.J., et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 65 (2004) 1440-1448
135. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262-268
136. de Groot K., and Jayne D. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol 64 (2005) 480-484
137. Jayne D., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (2003) 36-44
138. Stegeman C.A., Cohen Tervaert J.W., De Jong P.E., and Kallenberg C.G. Trimethoprim-Sulfamethoxazole (Co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N. Engl. J. Med. 335 (1996) 16-20
139. De Groot K., Reinhold-Keller E., Tatsis E., Paulsen J., Heller M., Nolle B., et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate vs trimethoprim/sulfamethoxazole. Arthritis Rheum. 39 (1996) 2052-2061
140. Langford C.A., Talar-Williams C., Barron K.S., and Sneller M.C. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum. 42 (1999) 2666-2673
141. Nowack R., Gobel U., Klooker P., Hergesell O., Andrassy K., and van der Woude F.J. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J. Am. Soc. Nephrol. 10 (1999) 1965-1971
142. Jayne D.R., Chapel H., Adu D., Misbah S., O'Donoghue D., Scott D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q. J. Med. 93 (2000) 433-439
143. Allen A., Pusey C., and Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 9 (1998) 1258-1263
144. Nachman P.H., Segelmark M., Westman K., Hogan S.L., Satterly K.K., Jennette J.C., et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int. 56 (1999) 1544-1550
145. Adu D. The evidence base for the treatment of lupus nephritis in the new millennium. Nephrol. Dial. Transplant. 16 (2001) 1536-1538
146. Chan T.M., Tse K.C., Tang CS Mok M.Y., and Li F.K. Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16 (2005) 1076-1084
147. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353 (2005) 2219-2228
148. Harper L., Ferreira M.A., Howie A.J., Savage C.O., Richards N.T., Michael J., et al. Treatment of vasculitic IgA nephropathy. J. Nephrol. 13 (2000) 360-366
149. Rocatello D., Ferro M., Coppo R., Giraudo G., Quattrocchio G., and Piccoli G. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol. Dial. Transplant. 10 (1995) 2054-2059
150. Kurki P., Helve T., von Bonsdorff M., Tornroth T., Pettersson E., Riska H., et al. Transformation of membranous glomerulonephritis into crescentic glomerulonephritis with glomerular basement membrane antibodies: serial determinations of anti-GBM before the transformation. Nephron 38 (1984) 134-137
151. Diaz-Gallo C., Mauri J.M., Poveda R., Castelao A.M., Gonzales M.T., Carreras M., et al. Renal amyloidosis associated with antiglomerular basement membrane disease. Nephron 56 (1990) 335-336
152. Thompson C.H., and Kalowski S. Anti-glomerular basement membrane nephritis due to hydralazine. Nephron 58 (1991) 238-239
153. Macarron P., Garcia Diaz J.E., Azofra J.A., Martin de Francisco J., Gonzales E., Fernandez G., et al. D-penicillamine therapy associated with rapidly progressive glomerulonephritis. Nephrol. Dial. Transplant. 7 (1992) 161-164
154. Hellmark T., Niles J.L., Collins A.B., McCluskey R.T., and Brunmark C. Comparison of anti-GBM antibodies in sera with and without ANCA. J. Am. Soc. Nephrol. 8 (1997) 376-385
155. Buka I., and Coovadia H.M. Typhoïd glomerulonephritis. Arch. Dis. Child. 55 (1980) 305-307
156. Pai P., Kumar S., Bell G.M., and Ahmad R. Rapidly progressive crescentic glomerulonephritis and Legionnaires'disease. Clin. Nephrol. 45 (1996) 209-210
157. Hruby Z., Kuzniar J., Rabczynski J., Bogucki J., Steciwko A., and Weyde W. The variety of clinical and histopathologic presentations of glomerulonephritis associated with latent syphilis. Int. Urol. Nephrol. 24 (1992) 541-547
158. Madiwale C.V., Mittal B.V., Dixit M., and Acharya V.N. Acute renal failure due to crescentic glomerulonephritis complicating leprosy. Nephrol. Dial. Transplant. 9 (1994) 178-179
159. Campbell J.H., Warwick G., Boulton-Jones L., Mclay A., Jackson B., and Stevenson R.D. Rapidly progressive glomerulonephritis and nephrotic syndrome associated with Mycoplasma pneumoniae pneumonia. Nephrol. Dial. Transplant. 6 (1991) 518-520
160. Sopena B., Sobrado J., Perez A.J., Olover J., Courel M., and Palomares L. Rapidly progressive glomerulonephritis and pulmonary tuberculosis. Nephron 57 (1991) 251-252
161. Biava C.G., Gonwa T.A., Naugton J.L., and Hopper Jr. J. Crescentic glomerulonephritis associated with nonrenal malignancies. Am. J. Nephrol. 4 (1984) 208-214
162. Rerolle J.P., Thervet E., Beaufils H., Vincent F., Rousselot P., Pillebout E., et al. Crescentic glomerulonephritis and centrocytic lymphoma. Nephrol. Dial. Transplant. 14 (1999) 1744-1745
163. Meyrier A., Simon P., Mignon F., Striker L., and Ramée M.P. Rapidly progressive ("crescentic") glomerulonephritis and monoclonal gammapathies. Nephron 38 (1984) 156-162
164. Moroni G., Banfi G., Maccario M., Mereghetti M., and Ponticelli C. Extracapillary glomerulonephritis and renal amyloidosis. Am. J. Kidney Dis. 28 (1996) 695-699
165. Orfila C., Meeus F., Bernadet P., Lepert J.C., and Suc J.M. Immunotactoid glomerulopathy and cutaneous vasculitis. Am. J. Nephrol. 11 (1991) 67-72
166. Casella F.J., and Allon M. The kidney in sarcoidosis. J. Am. Soc. Nephrol. 3 (1993) 1555-1562
167. Nguyen B.P., Reisin E., and Rodriguez Jr. F.H. Idiopathic membranous glomerulopathy complicated by crescentic glomerulonephritis and renal vein thrombosis. Am. J. Kidney Dis. 12 (1988) 326-328
168. Jones B., Trevillian P., Hibberd A., and White K. De novo crescentic glomerulonephritis in a renal transplant. Am. J. Kidney Dis. 16 (1990) 501-503
169. Geffriaud-Ricouard C., Noel L.H., Chauveau D., Houhou S., Grunfeld J.P., and Lesavre P. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin. Nephrol. 39 (1993) 125-136
170. Hellmann D.B., Hardy K., Lindenfeld S., and Ring E. Takayasu's arteritis associated with crescentic glomerulonephritis. Arthritis Rheum. 30 (1987) 451-454
171. Lenz T., Schmidt R., Scherberich J.E., and Grone H.J. Renal failure in giant cell vasculitis. Am. J. Kidney Dis. 31 (1998) 1044-1047
172. Eustace J.A., Nadasdy T., and Choi M. Disease of the month. The Churg Strauss syndrome. J. Am. Soc. Nephrol. 10 (1999) 2048-2055
173. Messiaen T., M'bappe P., Boffa J.J., Khayat R., Mougenot B., Rossert J., et al. MPO-ANCA necrotizing glomerulonephritis related to rheumatoid arthritis. Am. J. Kidney Dis. 32 (1998) E6
174. Karpinski J., Jothy S., Radoux V., Levy M., and Baran D. D-penicillamine-induced crescentic glomerulonephritis and antimyeloperoxidase antibodies in a patient with scleroderma. Case report and review of the literature. Am. J. Nephrol. 17 (1997) 528-532
175. Yoshida A., Morozumi K., Takeda A., Koyama K., Oikawa T., and Fujinami T. A case of rapidly progressive glomerulonephritis associated with bucillamine-treated rheumatoid arthritis. Am. J. Kidney Dis. 20 (1992) 411-413
176. Leung A.C., McLay A., Dobbie J.W., and Jones J.M. Phenylbutazone-induced systemic vasculitis with crescentic glomerulonephritis. Arch. Intern. Med. 145 (1985) 685-687
177. Yoshioka K., Satake N., Kasamatsu Y., Nakamura Y., and Shikata N. Rapidly progressive glomerulonephritis due to rifampicin therapy. Nephron 90 (2002) 116-118
178. Bailey R.R., and Lynn K.L. Crescentic glomerulonephritis developing in a patient taking enalapril. N. Z. Med. J. 99 (1986) 958-959
179. Murray N., Lyons J., and Chappel M. Crescentic glomerulonephritis: a possible complication of streptokinase treatment for myocardial infarction. Br. Heart J. 56 (1986) 483-485
180. Parker M.G., Atkins M.B., Ucci A.A., and Levey A.S. Rapidly progressive glomerulonephritis after immunotherapy for cancer. J. Am. Soc. Nephrol. 5 (1995) 1740-1744
181. Beaudreuil S., Lasfargues G., Laueriere L., El Ghoul Z., Fourquet F., Longuet C., et al. Occupational exposure in ANCA-positive patients: a case-control study. Kidney Int. 67 (2005) 1961-1966
182. Lechleitner P., Defregger M., Lhotta K., Tötsch M., and Fend F. Goodpasture's syndrome: unusual presentation after exposure to hard metal dust. Chest 103 (1993) 956-957
183. Ponticelli C., and Pezzagno G. Hydrocarbons and glomerulonephritis-is the definite answer in?. Nephrol. Dial. Transplant. 9 (1994) 1539-1540